Table 2.

Patient clinical characteristics of study groups after propensity score matching

	2OPMT group		CSWWD group		Std. Diff.*
N	5,338	100%	5,338	100%
Comorbidities, N/%
Alcohol abuse	183	3.40%	183	3.40%	0.000
Cancer	45	0.80%	55	1.00%	0.019
Cardiac arrhythmias	1,291	24.20%	1,344	25.20%	−0.023
Chronic pulmonary disease	1,287	24.10%	1,275	23.90%	0.005
Coagulopathy	399	7.50%	395	7.40%	0.003
Congestive heart failure	1,813	34.00%	1,821	34.10%	−0.003
Deficiency anemia	114	2.10%	118	2.20%	−0.005
Depression	549	10.3%	552	10.3%	−0.002
Diabetes, complicated	1,496	28.00%	1,502	28.10%	−0.003
Diabetes, uncomplicated	937	17.60%	933	17.50%	0.002
Drug abuse	174	3.30%	176	3.30%	−0.002
Hypertension, uncomplicated	2,675	50.10%	2,676	50.10%	0.000
Hypertension, complicated	2,123	39.80%	2,113	39.60%	0.004
Hypothyroidism	687	12.90%	673	12.60%	0.008
Liver disease	150	2.80%	160	3.00%	−0.011
Obesity	1,676	31.40%	1,687	31.60%	−0.004
Neurological disorders	162	3.00%	156	2.90%	0.007
Paralysis	13	0.20%	11	0.20%	0.008
Peripheral vascular disease	958	17.90%	985	18.50%	−0.013
Pulmonary circulation disorders	408	7.60%	418	7.80%	−0.007
Renal failure	1,181	22.10%	1,196	22.40%	0.007
RA/collagen vascular diseases	152	2.80%	138	2.60%	0.016
Valvular disease	1,870	35.00%	1,892	35.40%	−0.009
Weight loss	101	1.90%	108	2.00%	−0.009
CCI, N/%
0	694	13.00%	701	13.10%	−0.004
1–2	2,450	45.90%	2,432	45.60%	0.007
3–4	1,298	24.30%	1,309	24.50%	−0.005
5+	896	16.80%	896	16.80%	0.000

CCI Charlson Comorbidity Index; RA rheumatoid arthritis; Std. Diff. standardized mean difference

*A standardized mean difference with an absolute value ≤ 0.10 is considered to balanced